Clinical trials: Polycythemia, open to volunteers
Polycytemia Vera
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
This retrospective study aims to evaluate the effectiveness and safety of Ropeginterferon Alfa-2b (BESREMI) in patients with Polycythemia Vera (PV).
- Trial name
- MIRROR (NCT07282132)
- Testing
- Ropeginterferon alfa-2b (BESREMi®)
- Volunteers
- 150 people
- Sponsor
- Federico II University
Myelofibrosis (MF)
Momelotinib Effectiveness in Myelofibrosis
Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.
- Trial name
- NCT07249606
- Volunteers
- 93 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic…
- Conditions
- Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT06063486
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Southern California
Myeloproliferative Neoplasm, Polycythemia Vera
Asian Myeloproliferative Neoplasm (MPN) Registry
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
- Conditions
- Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Post-polycythemia Vera Myelofibrosis
- Trial name
- NCT05882773
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- The University of Hong Kong
Myeloproliferative Neoplasms
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in…
- Trial name
- NCT07441694
- Testing
- INCA036978, Standard disease-directed therapy
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 218 people
- Sponsor
- Incyte Corporation
Polycythemia Vera
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any…
- Trial name
- MITHRIDATE (NCT04116502)
- Testing
- Ruxolitinib, Hydroxycarbamide, Interferon-Alpha
- Where
- 55 sites in United Kingdom
- Volunteers
- 586 people
- Sponsor
- University of Birmingham
Primary Myelofibrosis, Secondary Myelofibrosis
Research Platform Myelofibrosis and Anemia
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- RHODOLITE (NCT06976918)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- iOMEDICO AG
Polycythemia, Polycythemia Vera (PV)
Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera
Polycythemia vera (PV) is a rare haematological disorder characterized by an excessive production of red blood cells, associated with the somatic JAK2 V617F mutation.
- Trial name
- ACTIVAQ (NCT07341048)
- Testing
- Research samples blood viscosity and viscoelasticity:
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hospices Civils de Lyon
Polycythemia Vera (PV), Myelofibrosis (MF)
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F.
- Trial name
- NCT07529951
- Testing
- ZE74-0282
- Volunteers
- 60 people
- Sponsor
- Eilean Therapeutics
Polycythemia Vera
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative…
- Trial name
- STANDARDIZE-PV (NCT07734272)
- Testing
- Standardized progress note
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Primary Myelofibrosis, Polycythemia Vera
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis
- Trial name
- NCT02760238
- Testing
- Observational
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- University Health Network, Toronto
Twin to Twin Transfusion Syndrome, Twin Anemia-Polycythemia Sequence
Evaluation of Laparotomy With Trans-Amniotic Suture Placement in TTTS Surgery
This is a randomized trial for patients that are diagnosed with Twin-Twin Transfusion Syndrome (TTTS) who are receiving a fetoscopic laser surgery to evaluate the effectiveness and safety of a laparotomy closure.
- Trial name
- TTTS TAPS (NCT06991400)
- Testing
- Trans-Amniotic Suture Placement
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension
129Xe MRI Cardiopulmonary
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
- Conditions
- Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia
- Trial name
- NCT06038630
- Testing
- Hyperpolarized Xe129, Oxygen Administration
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT07447817
- Testing
- Pacritinib, Selinexor
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- John Mascarenhas
Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Revumenib in Patients With Myelofibrosis
This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis.
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- MPN-RC 129 (NCT07734077)
- Testing
- Revumenib, Ruxolitinib, FEDRATINIB
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- John Mascarenhas
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
- Trial name
- NCT06327100
- Testing
- Ruxolitinib, Tasquinimod
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Polycythemia
Effect of Phlebotomy on Heartrate in Polycythemia Patients
Single-centre, observational within-subject design: patients that undergo phlebotomies regularly for polycythemia will be measured continuously by wearables one week before until one week after a phlebotomy, for three…
- Trial name
- NOSFERATU (NCT05396170)
- Testing
- phlebotomy
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).
- Conditions
- Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06661915
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 31 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Essential Thrombocythemia, Polycythemia Vera
Ruxolitinib in Thrombocythemia and Polycythemia Vera
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- Trial name
- NCT04644211
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Polycythemia Vera (PV)
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
- Trial name
- NCT04655092
- Testing
- P1101 (Ropeginterferon alfa-2b)
- Where
- 6 sites in Japan
- Volunteers
- 67 people
- Sponsor
- PharmaEssentia Japan K.K.